CAR-PLT
Live / Applied — First extension granted (statement of use) (as of 27 Oct 2025)
What this means for you
Not registered yet, but its 27 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98105723
- Mark type
- Stylized text
- Filed
- 27 Jul 2023
- Published for opposition
- 29 Apr 2025
- Attorney of record
- Jonathan A. Hyman
Goods and services
- Class 005 — Pharmaceuticals: Medicinal infusions for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drugs for medical purposes, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Therapeutic drugs and agents, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents in the form of infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion that facilitate the delivery of proteins, peptides, long and short RNA, siRNA, miRNA, and saRNA; Drug delivery agents in the form of infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Medicines for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pre-filled syringes and infusion bags for medical purposes featuring pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents infused in a patient's blood consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
- Class 042 — Scientific and technological services: Testing and analysis of blood plasma, red blood cells, white blood cells, blood platelets for scientific research purposes
- Class 044 — Medical, beauty and agricultural services: Platelet-rich plasma therapy; blood banks
Owner
- HemostOD SA, Saint-Sulpice, CH
- HemostOD SA, Saint-Sulpice, CH
Prosecution history
- 28 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Oct 2025 — SOU EXTENSION 1 GRANTED
- 27 Oct 2025 — SOU EXTENSION 1 FILED
- 27 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Apr 2025 — PUBLISHED FOR OPPOSITION
- 23 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Mar 2025 — EXAMINER'S AMENDMENT ENTERED
- 31 Mar 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 31 Mar 2025 — EXAMINERS AMENDMENT E-MAILED
- 31 Mar 2025 — EXAMINERS AMENDMENT -WRITTEN
- 17 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 17 Jan 2025 — NON-FINAL ACTION E-MAILED